General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-22 | 2024-03 | -0.29 | N/A | N/A | N/A |
2024-03-26 | 2023-12 | -0.22 | -0.15 | 0.07 | 31.82% |
2023-11-20 | 2023-09 | -0.18 | -0.3 | -0.12 | -66.67% |
2023-08-30 | 2023-06 | -0.16 | -0.3 | -0.14 | -87.50% |
2023-05-24 | 2023-03 | -0.14 | -0.15 | -0.01 | -7.14% |
2023-03-22 | 2022-12 | -0.14 | -0.09 | 0.05 | 35.71% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-30 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-05-24 | Oppenheimer | Upgrade | Outperform | |
2021-02-22 | HC Wainwright & Co. | Upgrade | Buy | |
2020-12-15 | HC Wainwright & Co. | Upgrade | Buy | |
2017-08-03 | Oppenheimer | Upgrade | Outperform |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Morgan Stanley | 260.98K | 416.26K | 0.42% |
2023-06-29 | Citadel Advisors Llc | 212.77K | 339.37K | 0.35% |
2023-06-29 | LPL Financial LLC | 125.21K | 199.71K | 0.20% |
2023-06-29 | Atria Wealth Solutions, Inc. | 110.37K | 176.03K | 0.18% |
2023-06-29 | Renaissance Technologies, LLC | 98.71K | 157.44K | 0.16% |
2023-06-29 | Susquehanna International Group, LLP | 84.10K | 134.14K | 0.14% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-05-30 | Fidelity NASDAQ Composite Index Fund | 32.03K | 50.44K | 0.05% |
Split | Date |
---|---|
1 : 15 | 2019-07-15 |
On track for September 9, 2023 PDUFA target action date on NDA for motixafortide in stem cell mobilization for autologous transplantation in multiple myeloma
Signed exclusive license agreement to develop and commercialize motixafortide in Asia with concurrent equity investment; license agreement includes $15 million upfront payment, plus potential development, regulatory and sales milestones, and tiered double-digit royalties, as well as various development obligations for the licensee, including the planned initiation in China of a registrational study in stem-cell mobilization and a randomized Phase 2/3 study in first-line pancreatic cancer; straight common equity investment of $14.6 million in BioLineRx at $2.136 per ADS with no warrants; effectiveness and closing of transactions is contingent upon approval by Israeli Innovation Authority of license agreement within four months of execution, and other closing conditions
Clinical Portfolio Updates
Seems like infinite shares being bought at $2 and it’s not budging…once through should at least test HOD